Archie N Tse

Archie N Tse

UNVERIFIED PROFILE

Are you Archie N Tse?   Register this Author

Register author
Archie N Tse

Archie N Tse

Publications by authors named "Archie N Tse"

Are you Archie N Tse?   Register this Author

9Publications

206Reads

19Profile Views

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.

J Clin Oncol 2015 Aug 29;33(24):2609-16. Epub 2015 Jun 29.

Marika Ciprotti, Niall C. Tebbutt, Fook-Thean Lee, Sze-Ting Lee, Hui K. Gan, Wendie Hopkins, Fiona E. Scott, Andrew M. Scott, Ludwig Institute for Cancer Research; David C. McKee, Graeme J. O'Keefe, Sylvia J. Gong, Geoffrey Chong, Bridget Chappell, Andrew M. Scott, Austin Health, Melbourne, Australia; Martin W. Brechbiel, National Cancer Institute, Bethesda, MD; Archie N. Tse, Jonathan Greenberg, Daiichi Sankyo Co., Ltd, Parsippany, NJ; Mendel Jansen, Daiichi Sankyo Development Ltd, Gerrards Cross, Buckinghamshire, United Kingdom; Manabu Matsumura, Masakatsu Kotsuma, Rira Watanabe, Daiichi Sankyo Co., Ltd, Tokyo, Japan; Robert A. Beckman, Georgetown University Medical Center and Ralph Venhaus, Ludwig Institute for Cancer Research, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.60.4256
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.60.4256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881374PMC
August 2015

A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies.

Cancer Chemother Pharmacol 2009 Oct 17;64(5):935-44. Epub 2009 Feb 17.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-009-0945-5DOI Listing
October 2009

90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.

Mol Pharmacol 2009 Jan 26;75(1):124-33. Epub 2008 Sep 26.

Laboratory of New Drug Development, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.108.050807DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685054PMC
January 2009

Targeting checkpoint kinase 1 in cancer therapeutics.

Clin Cancer Res 2007 Apr;13(7):1955-60

Authors' Affiliations: Gastrointestinal Oncology Service and Melanoma and Sarcoma Service, Division of Solid Tumor Oncology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-2793DOI Listing
April 2007

CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.

Clin Cancer Res 2007 Jan;13(2 Pt 1):591-602

Laboratory of New Drug Development, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1424DOI Listing
January 2007

Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.

Cancer Res 2004 Sep;64(18):6635-44

Gastrointestinal Oncology Research Laboratory, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-0841DOI Listing
September 2004